查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1905016

全球连续生物製程市场：依产品、应用、最终用途及地区划分的分析－市场规模、产业趋势、机会分析及2026年至2035年预测

Global Continuous Bioprocessing Market: Analysis By Product, Application, End Use, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

连续生物製程市场持续快速扩张，反映出其在生物製药製造领域日益增长的重要性。 2025年，该市场规模为3.1977亿美元，预计到2035年将显着成长至23.3198亿美元。这项预测成长在2026年至2035年的预测期内复合年增长率（CAGR）为21.98%，显示在多种影响产业的因素支撑下，该市场保持强劲且持续的成长动能。

这一成长的核心在于对提高生物製造製程效率的日益增长的需求。与传统的间歇式製程相比，连续生物製程具有显着优势，能够实现不间断生产，减少停机时间，并最大限度地提高产量。这种效率的提昇在复杂生物製剂（例如抗体和疫苗）的生产中尤其重要，因为在这些产品中，保持品质稳定和满足大批量需求至关重要。更快、更可靠地生产治疗药物，能够帮助製造商更有效地应对公共卫生需求和市场压力。

值得关注的市场趋势

连续生物製程市场由四家公司主导：赛默飞世尔科技 (Thermo Fisher Scientific)、赛多利斯 (Sartorius)、丹纳赫 (Danaher)（旗下拥有 CytIV.a 和 Pall 两大部门）以及默克集团 (Merck KGaA，以 MilliporeSigma 的名义开展业务）。这四家公司共同为产业成长和创新提供了基础架构。

这些公司提供各种先进的设备、耗材和整合解决方案，帮助生物製药製造商有效地采用和扩展连续生物製程技术。他们的领先地位源于丰富的专业知识、全球影响力以及致力于开发尖端工具以满足不断发展的生物工艺工作流程需求的承诺。

产业内的策略联盟正在进一步增强连续生物製程的普及势头。 2025年12月，全球临床阶段生物製药公司Transcenta Therapeutics宣布与台湾合约开发和生产机构（CDMO）Irigenix达成重要合作。此次合作包括一项关于Irigenix高度整合连续生物製程（HiCB）平台的非独家授权协议。

同时，为满足日益增长的生物製药及相关生物製程材料需求，生产能力方面的投资也持续扩大。 2025年7月，旭化成生命科学宣布计画在日本新建一座纺丝工厂，专门生产Planova™病毒去除过滤器。该设施计划于 2030 年投入运营，届时将加强关键过滤产品的供应，这些产品对于在整个生产过程中维持生物製药的安全性和纯度至关重要。

核心成长驱动因子

全球对疫苗、抗体、生物相似药以及细胞和基因疗法的需求不断增长，是推动连续生物製程技术应用的关键催化剂。随着全球医疗保健系统面临越来越大的压力，需要快速、大规模地提供创新疗法，生物製药製造商正越来越多地转向连续生物製程技术来应对这些复杂的生产挑战。这种需求的激增反映了医疗保健行业的更广泛趋势，包括慢性病的增加、个人化医疗的进步以及对有效疫苗以对抗新兴传染病的持续需求。

新兴机会

对永续性和数位化整合的双重关注正日益影响着连续生物製程市场，这反映了整个产业向环保和技术先进的生产方法转变的趋势。环境责任已不再只是企业社会责任 (CSR) 活动，而已成为一项根本性的业务要务。这项转变也清楚地体现在产业领导者设定的优先事项中，62% 的生物製药主管将永续发展列为首要任务。这种高度重视凸显了永续实践在塑造产业策略决策和营运方式方面发挥的关键作用。

优化障碍

儘管人们对连续生物工艺的采用和发展普遍持乐观态度，但在充分发挥其潜力方面仍然存在重大挑战。其中最迫切的挑战是人才短缺。操作连续生产线需要专门的技能，这与传统间歇式生产所需的专业知识截然不同。这种转变对许多寻求采用和扩展这项先进技术的组织构成了重大障碍。

目录

第一章：摘要整理：全球连续生物工艺市场

第二章：研究方法与架构

  • 研究目标
  • 产品概述
  • 市场区隔
  • 质性研究
    • 一手和二手资料来源
  • 量化研究
    • 一手和二手资料来源
  • 按地区划分的原始调查受访者
  • 研究假设
  • 市场规模估算
  • 资料三角验证

第三章：全球连续生物工艺市场概论

  • 产业价值链分析
    • 服务提供者
    • 最终用户用户
  • 行业展望
    • 全球研发支出
    • 全球主要生物技术中心（2025 年）
  • PESTLE 分析
  • 波特五力分析
    • 供应商议价能力
    • 买方议价能力
    • 替代品威胁
    • 新进入者威胁
    • 竞争强度
  • 市场成长与展望
    • 市场收入估计与预测（2020-2035 年）
    • 依产品类型划分的价格趋势分析
  • 市场吸引力分析
    • 依产品类型划分
    • 按地区划分
  • 可操作的洞见（分析师）建议）

第四章：竞争格局概览

  • 市场集中度
  • 公司占有率分析（基于价值，2025 年）
  • 竞争格局分析与基准分析

第五章：全球连续生物製程市场分析

  • 市场动态与趋势
    • 成长驱动因素
    • 限制因素
    • 机遇
    • 关键趋势
  • 市场规模及预测（2020-2035 年）
    • 依产品类型划分
      • 设备
      • 生物反应器
      • 过滤系统
      • 色谱系统
      • 过程分析技术
      • 其他
      • 耗材和试剂
      • 培养基和缓衝液
      • 过滤器和薄膜
      • 树脂
      • 试管和试袋
      • 其他
    • 按应用领域
      • 单株抗体
      • 疫苗
      • 细胞和基因治疗
      • 研发
      • 其他应用
    • 依最终用途
      • 製药和生技公司
      • 合约生产组织 (CMO) 和合约研究组织 (CRO)
      • 研究机构和学术机构
    • 按地区

第六章：北美连续生物製程市场分析

第七章：欧洲连续生物製程市场分析

章节第八章：亚太地区连续生物製程市场分析

第九章：中东和非洲连续生物製程市场分析

第十章：南美洲连续生物製程市场分析

第十一章：公司简介

  • 富士软片控股株式会社
  • 岛津公司
  • Bionet
  • 丹纳赫公司
  • Eppendorf SE
  • 默克集团
  • Repligen Corporation
  • 赛多利斯公司
  • 赛默飞世尔科技公司
  • 药明生物
  • 其他主要企业

第十二章附录

简介目录
Product Code: AA01261635

The continuous bioprocessing market is undergoing rapid expansion, reflecting its increasing importance in the biopharmaceutical manufacturing landscape. Valued at USD 319.77 million in 2025, the market is poised for remarkable growth, with projections estimating it will reach a valuation of USD 2,331.98 million by 2035. This anticipated growth translates to a compound annual growth rate (CAGR) of 21.98% over the forecast period from 2026 to 2035, signaling strong and sustained momentum fueled by multiple factors influencing the industry.

At the core of this growth is the rising demand for greater efficiency in biomanufacturing processes. Continuous bioprocessing offers significant advantages over traditional batch methods by enabling uninterrupted production, which reduces downtime and maximizes output. This efficiency gain is particularly valuable in the production of complex biologics such as antibodies and vaccines, where maintaining consistent quality and meeting high-volume demand are critical. The ability to produce therapies more quickly and reliably allows manufacturers to respond more effectively to public health needs and market pressures.

Noteworthy Market Developments

The continuous bioprocessing market is dominated by four key players-Thermo Fisher Scientific, Sartorius, Danaher (through its Cytiva and Pall divisions), and Merck KGaA (operating as MilliporeSigma)-who collectively provide the essential infrastructure that underpins the industry's growth and innovation.

These companies supply a broad range of advanced equipment, consumables, and integrated solutions that enable biopharmaceutical manufacturers to implement and scale continuous bioprocessing technologies effectively. Their leadership is rooted in extensive expertise, global reach, and a commitment to developing cutting-edge tools that address the evolving needs of bioprocessing workflows.

Strategic collaborations within the industry further reinforce the momentum toward continuous bioprocessing adoption. In December 2025, Transcenta Therapeutics, a global clinical-stage biopharmaceutical company, announced a significant partnership with EirGenix, a Contract Development and Manufacturing Organization (CDMO) based in Taiwan. This collaboration involves a non-exclusive licensing agreement for EirGenix's highly intensified continuous bioprocessing (HiCB) platform.

Meanwhile, investments in manufacturing capacity continue to expand in response to growing demand for biologics and related bioprocessing materials. In July 2025, Asahi Kasei Life Science announced plans to establish a new spinning plant in Japan dedicated to producing Planova(TM) virus removal filters. Scheduled to begin operations in 2030, this facility will enhance the supply of critical filtration products essential for maintaining the safety and purity of biologics throughout their manufacturing processes.

Core Growth Drivers

The rising global demand for vaccines, antibodies, biosimilars, and cell and gene therapies is a significant catalyst driving the adoption of continuous bioprocessing technologies. As healthcare systems worldwide face mounting pressure to deliver innovative treatments rapidly and at scale, biopharmaceutical manufacturers are increasingly turning to continuous bioprocessing to meet these complex production challenges. This surge in demand reflects broader trends in medicine, including the growing prevalence of chronic diseases, advancements in personalized therapies, and the ongoing need for effective vaccines to combat emerging infectious diseases.

Emerging Opportunity Trends

The continuous bioprocessing market is increasingly influenced by a dual emphasis on sustainability and digital integration, reflecting broader industry shifts toward environmentally responsible and technologically advanced manufacturing practices. Environmental responsibility has transcended being a mere corporate social responsibility initiative and has become a fundamental business imperative. This shift is evident in the priorities set by industry leaders, with a striking 62% of biopharma executives identifying sustainability as their foremost concern. Such a strong focus underscores the critical role that sustainable practices play in shaping strategic decisions and operational approaches within the sector.

Barriers to Optimization

Despite the widespread optimism surrounding the adoption and advancement of continuous bioprocessing, significant challenges continue to hinder its full potential. Among these, the most pressing issue is the talent gap within the workforce. Operating continuous manufacturing lines demands a specialized skillset that differs substantially from the expertise required for traditional batch processing. This transition poses a significant obstacle for many organizations as they strive to implement and scale these advanced technologies.

Detailed Market Segmentation

By Product, the consumables and reagents segment dominated the continuous bioprocessing market. This reflects its critical role in maintaining seamless and sterile operations within biomanufacturing processes. These consumables, which include single-use components such as filters, tubing, bags, and various reagents, are essential for ensuring that bioprocessing environments remain contamination-free and that product integrity is preserved throughout production. The reliance on disposable materials helps eliminate cross-contamination risks that can occur with reusable equipment, making them indispensable in continuous manufacturing systems that require stringent sterility standards.

By Application, the monoclonal antibody (mAb) segment maintains a dominant position in the continuous bioprocessing market. Monoclonal antibodies have become a cornerstone of modern therapeutics, widely used to treat a variety of diseases, including cancers, autoimmune disorders, and infectious diseases. Their proven efficacy and growing demand have driven sustained investment and innovation within this application segment, reinforcing its leadership in the bioprocessing landscape.

By End Use, the pharmaceutical and biotechnology segment continues to serve as the undisputed driving force behind the growth of the continuous bioprocessing market. This sector's strong demand for efficient, scalable, and flexible production methods has positioned it at the forefront of adopting continuous bioprocessing technologies. Unlike traditional approaches that rely on batch processing, continuous bioprocessing offers significant advantages such as reduced production times, improved product consistency, and enhanced cost efficiency-all critical factors for pharmaceutical and biotech companies aiming to meet growing global demand for innovative therapies.

Segment Breakdown

By Product

  • Instruments
  • Bioreactors
  • Filtration Systems
  • Chromatography Systems
  • Process Analytical Technologies
  • Others
  • Consumables & Reagents
  • Media & Buffers
  • Filters & Membranes
  • Resin
  • Tubing & Bags
  • Others

By Application

  • Monoclonal antibodies
  • Vaccines
  • Cell and gene therapy
  • Research & Development
  • Other applications

By End Use

  • Pharmaceutical and biotechnology companies
  • CMOs and CROs
  • Research and academic institutes

By Region

  • North America
  • The US
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia and New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America holds a commanding 39% share of the global continuous bioprocessing market, solidifying its position as the epicenter of innovation and adoption in this rapidly evolving sector. This leadership is the result of a combination of strategic investments, advanced technological capabilities, and a supportive regulatory environment that together foster an ecosystem conducive to growth and development. The region's dominance reflects its ability to pioneer new bioprocessing techniques and implement them at scale, setting benchmarks for the industry worldwide.
  • A key factor underpinning North America's market leadership is the aggressive capital deployment by major pharmaceutical and biotech players. For example, Sanofi's commitment to invest USD 20 billion in manufacturing and research and development across the United States through 2030 exemplifies the scale of financial resources being directed toward advancing continuous bioprocessing technologies.
  • Regulatory confidence further strengthens the region's dominance in the continuous bioprocessing market. The U.S. Food and Drug Administration (FDA) plays a crucial role by fostering a regulatory environment that encourages innovation while ensuring safety and efficacy. In 2024 alone, the FDA approved 48 novel drugs, signaling robust support for new therapies and the processes that bring them to market.

Leading Market Participants

  • FUJIFILM HOLDINGS CORPORATION
  • Shimadzu Corporation
  • Bionet
  • Danaher Corporation
  • Eppendorf SE
  • Merck KGaA
  • Repligen Corporation
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • WuXi Biologics
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Continuous Bioprocessing Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Continuous Bioprocessing Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Service Provider
    • 3.1.2. End Consumers
  • 3.2. Industry Outlook
    • 3.2.1. Global R&D Expenditure
    • 3.2.2. Top Biotechnology Hubs in the World, 2025
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Product Type
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Product Type
    • 3.6.2. By Region
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Continuous Bioprocessing Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Product Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Instruments
          • 5.2.1.1.1.1. Bioreactors
          • 5.2.1.1.1.2. Filtration Systems
          • 5.2.1.1.1.3. Chromatography Systems
          • 5.2.1.1.1.4. Process Analytical Technologies
          • 5.2.1.1.1.5. Others
        • 5.2.1.1.2. Consumables & Reagents
          • 5.2.1.1.2.1. Media & Buffers
          • 5.2.1.1.2.2. Filters & Membranes
          • 5.2.1.1.2.3. Resin
          • 5.2.1.1.2.4. Tubing & Bags
          • 5.2.1.1.2.5. Others
    • 5.2.2. By Application
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Monoclonal antibodies
        • 5.2.2.1.2. Vaccines
        • 5.2.2.1.3. Cell and gene therapy
        • 5.2.2.1.4. Research & Development
        • 5.2.2.1.5. Other applications
    • 5.2.3. By End Use
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Pharmaceutical and biotechnology companies
        • 5.2.3.1.2. CMOs and CROs
        • 5.2.3.1.3. Research and academic institutes
    • 5.2.4. By Region
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. North America
          • 5.2.4.1.1.1. The U.S.
          • 5.2.4.1.1.2. Canada
          • 5.2.4.1.1.3. Mexico
        • 5.2.4.1.2. Europe
          • 5.2.4.1.2.1. Western Europe
            • 5.2.4.1.2.1.1. The UK
            • 5.2.4.1.2.1.2. Germany
            • 5.2.4.1.2.1.3. France
            • 5.2.4.1.2.1.4. Italy
            • 5.2.4.1.2.1.5. Spain
            • 5.2.4.1.2.1.6. Rest of Western Europe
          • 5.2.4.1.2.2. Eastern Europe
            • 5.2.4.1.2.2.1. Poland
            • 5.2.4.1.2.2.2. Russia
            • 5.2.4.1.2.2.3. Rest of Eastern Europe
        • 5.2.4.1.3. Asia Pacific
          • 5.2.4.1.3.1. China
          • 5.2.4.1.3.2. India
          • 5.2.4.1.3.3. Japan
          • 5.2.4.1.3.4. South Korea
          • 5.2.4.1.3.5. Australia & New Zealand
          • 5.2.4.1.3.6. ASEAN
              • 5.2.4.1.3.6.1.1. Indonesia
              • 5.2.4.1.3.6.1.2. Malaysia
              • 5.2.4.1.3.6.1.3. Thailand
              • 5.2.4.1.3.6.1.4. Singapore
              • 5.2.4.1.3.6.1.5. Rest of ASEAN
          • 5.2.4.1.3.7. Rest of Asia Pacific
        • 5.2.4.1.4. Middle East & Africa
          • 5.2.4.1.4.1. UAE
          • 5.2.4.1.4.2. Saudi Arabia
          • 5.2.4.1.4.3. South Africa
          • 5.2.4.1.4.4. Rest of MEA
        • 5.2.4.1.5. South America
          • 5.2.4.1.5.1. Argentina
          • 5.2.4.1.5.2. Brazil
          • 5.2.4.1.5.3. Rest of South America

Chapter 6. North America Continuous Bioprocessing Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By End Use
    • 6.2.4. By Country

Chapter 7. Europe Continuous Bioprocessing Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By End Use
    • 7.2.4. By Country

Chapter 8. Asia Pacific Continuous Bioprocessing Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End Use
    • 8.2.4. By Country

Chapter 9. Middle East & Africa Continuous Bioprocessing Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By End Use
    • 9.2.4. By Country

Chapter 10. South America Continuous Bioprocessing Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By End Use
    • 10.2.4. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. FUJIFILM HOLDINGS CORPORATION
  • 11.2. Shimadzu Corporation
  • 11.3. Bionet
  • 11.4. Danaher Corporation
  • 11.5. Eppendorf SE
  • 11.6. Merck KGaA
  • 11.7. Repligen Corporation
  • 11.8. Sartorius AG
  • 11.9. Thermo Fisher Scientific Inc.
  • 11.10. WuXi Biologics
  • 11.11. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Leather Types
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators